Anti-C5a 抗体 [EPR19699-24] (ab202039)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR19699-24] to C5a
- Suitable for: WB, IP
- Reacts with: Human
Related conjugates and formulations
製品の概要
-
製品名
Anti-C5a antibody [EPR19699-24]
C5a 一次抗体 製品一覧 -
製品の詳細
Rabbit monoclonal [EPR19699-24] to C5a -
由来種
Rabbit -
アプリケーション
適用あり: WB, IPmore details
適用なし: IHC-P -
種交差性
交差種: Human -
免疫原
Recombinant fragment. This information is proprietary to Abcam and/or its suppliers.
-
ポジティブ・コントロール
- WB: Human serum. IP: Human serum.
-
特記事項
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
バッファー
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: PBS, 0.05% BSA, 40% Glycerol (glycerin, glycerine) -
Concentration information loading...
-
精製度
Protein A purified -
ポリ/モノ
モノクローナル -
クローン名
EPR19699-24 -
アイソタイプ
IgG
関連製品
-
Alternative Versions
-
Compatible Secondaries
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab202039の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
WB |
1/1000.
|
|
IP |
1/30.
|
特記事項 |
---|
WB
1/1000. |
IP
1/30. |
ターゲット情報
-
関連性
Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation. -
参照データベース
- Entrez Gene: 727 Human
- SwissProt: P01031 Human
画像
-
Anti-C5a antibody [EPR19699-24] (ab202039) at 1/1000 dilution + Human serum at 20 µg
Secondary
VeriBlot for IP Detection Reagent (HRP) (ab131366) at 1/1000 dilution
Exposure time: 3 minutesC5 is cleaved into C5α and C5β and this antibody recognizes the C5α. The molecular weight observed is consistent with what has been described in the literature (PMID: 23401592)
-
C5a was immunoprecipitated from 0.35 mg human serum 10μg with ab202039 at 1/30 dilution (2μg in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab202039 at 1/2000 dilution (0.26 μg/ml). VeriBlot for IP Detection Reagent (HRP) (ab131366) was used at 1/10,000 dilution.
Lane 1: Human serum 10μg.
Lane 2: ab202039 IP in human serum.
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab202039 in human serum.
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 10 seconds.
This antibody recognizes C5a.
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
データシートおよび資料
-
SDS download
-
Datasheet download
Certificate of Compliance
参考文献 (2)
ab202039 は 2 報の論文で使用されています。
- Qin R et al. α2,6-Sialylation Is Upregulated in Severe COVID-19, Implicating the Complement Cascade. ACS Infect Dis 8:2348-2361 (2022). PubMed: 36219583
- Huang Z et al. Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting complement activation and upregulation of miR-499. Exp Ther Med 22:684 (2021). PubMed: 33986849